

Tetraspecific Antibodies Clinical Trials, Proprietary Technologies, Companies & Market Trends Insight 2023

<https://marketpublishers.com/r/T9932404DF7AEN.html>

Date: March 2023

Pages: 78

Price: US\$ 3,300.00 (Single User License)

ID: T9932404DF7AEN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Tetraspecific Antibodies Clinical Trials, Proprietary Technologies, Companies & Market Trends Insight 2023 Report Highlights:

Global Tetraspecific Clinical Trials Landscape Insight

Global Tetraspecific Ongoing Clinical Trials By Company, Country, Indication & Phase

Tetraspecific Antibodies Proprietary Technologies By Company

Current Clinical Development & Future Commercialization Outlook

Tetraspecific Antibodies Mono & Combination Therapeutic Approaches

Competitive Landscape

The field of antibody therapeutics has been rapidly evolving in recent years, and one of the most exciting developments has been the transition from monoclonal to bispecific to the now emerging tetraspecific antibodies. These new generation antibodies have the potential to offer more targeted and effective therapies for a range of diseases and conditions. Traditionally, monoclonal antibodies have been used in the development of therapeutics. These are antibodies that are designed to target a single antigen or

protein, and have been effective in treating a range of diseases, including cancer, autoimmune disorders, and infectious diseases.

However, tetraspecific antibodies offer a new level of selectivity and flexibility in targeted therapy approach. These multispecific antibodies are designed to target four different antigens or proteins, making them more targeted and effective in treating complex diseases and conditions. Tetraspecific antibodies can be used to target multiple pathways or receptors that are involved in disease progression, allowing for a more comprehensive and personalized approach to treatment. The potential of tetraspecific antibodies has been demonstrated in preclinical and clinical studies, with promising results in the treatment of cancer, autoimmune disorders, and infectious diseases. These antibodies have shown improved efficacy and safety compared to monoclonal antibodies, and have the potential to revolutionize the field of antibody therapeutics.

The swift change in the treatment landscape to tetraspecific antibodies represents an exciting new chapter in the field of antibody based therapies. With their increased specificity and versatility, tetraspecific antibodies have the potential to offer more targeted and effective therapies for a range of diseases and conditions. There are a number of companies that are currently developing tetraspecific antibodies, including some of the largest pharmaceutical companies in the world. These companies are investing heavily in research and development, and are working to bring these new therapies to market as quickly as possible. As research and development in this area continues, we can expect to see more exciting developments in the years to come.

The development of tetraspecific antibodies has created a highly competitive landscape in the field of antibody therapeutics. With their potential to offer more targeted and effective therapies for a range of diseases and conditions, many companies are investing heavily in the research and development of these new generation antibodies. The global market for tetraspecific antibodies is expected to grow significantly in the coming years, driven by increasing demand for more effective and personalized therapies.

For now, China, in particular, is poised to play a key role in the growth of the tetraspecific antibody market. Becoming the first country to step forward into the idea has given China an exciting advantage. Even though the notion is now adopted by US based pharmaceuticals companies as well, China might still continue to lead the clinical development for a long time. The country's biotech industry has seen significant investment in recent years, with the government providing favorable policies and regulatory support to encourage innovation and growth. Chinese biotech companies

have already made significant progress in the development of monoclonal antibodies and other innovative therapies, and are well-positioned to capitalize on the growing demand for tetraspecific antibodies. As such, the demand for tetraspecific antibodies is likely to increase in the coming years, as researchers and pharmaceutical companies work to develop more targeted and personalized treatments.

As per Tetraspecific Antibodies Clinical Trials, Proprietary Technologies, Companies & Market Trends Insight 2023 report findings, the future market outlook for tetraspecific antibodies looks promising. As the clinical research for tetraspecific antibodies continues to grow, we can expect to see more exciting developments in the years to come. With their potential to offer more targeted and effective therapies for a range of diseases and conditions, these new generation antibodies have the potential to revolutionize the field of antibody therapeutics and improve the lives of millions of people around the world. With its supportive regulatory environment and growing biotech industry, China along with its western counterparts is well-positioned to play a key role in the growth of this innovative and exciting sector. As such, investors and stakeholders should keep a close eye on the emerging opportunities in the tetraspecific antibody market.

Contents

1. INTRODUCTION TO TETRASPECIFIC ANTIBODIES

- 1.1 Clinical Overview
- 1.2 History & Development

2. TETRASPECIFIC ANTIBODIES MECHANISM OF ACTION

- 2.1 Multispecific Formats
- 2.2 Tetraspecific Antibodies Bringing Immune Cells & Target Cells Closer

3. GLOBAL TETRASPECIFIC ONGOING CLINICAL TRIALS BY COMPANY, COUNTRY, INDICATION & PHASE

- 3.1 By Company
- 3.2 By Country
- 3.3 By Indication
- 3.4 By Phase

4. GLOBAL TETRASPECIFIC ONGOING CLINICAL TRIALS INSIGHT

- 4.1 Research
- 4.2 Preclinical
- 4.3 Phase-I
- 4.4 Phase-II

5. TETRASPECIFIC ANTIBODIES PROPRIETARY TECHNOLOGIES BY COMPANY

- 5.1 Available Proprietary Platforms
- 5.2 Potential Proprietary Platforms

6. CURRENT CLINICAL DEVELOPMENT & FUTURE COMMERCIALIZATION OUTLOOK

- 6.1 Current Scenario
- 6.2 Future Market Commercialization Outlook

7. TETRASPECIFIC ANTIBODIES THERAPEUTIC APPROACHES

- 7.1 Tetraspecific Antibodies As Monotherapy
- 7.2 Tetraspecific Antibodies As Combinational Therapy
- 7.3 Tetraspecific Antibodies As Targeted Approach

8. TETRASPECIFIC ANTIBODIES THERAPEUTIC APPLICATION IN CANCER

- 8.1 Overview
- 8.2 Ongoing Research & Development

9. COMPETITIVE LANDSCAPE

- 9.1 Innate Pharma
- 9.2 ModeX Therapeutics (OPKO Health)
- 9.3 Ruijin Hospital
- 9.4 Sichuan Baili Pharmaceutical
- 9.5 SystImmune

List Of Figures

LIST OF FIGURES

Figure 1-1: FL518 - Structure

Figure 1-2: CRTB6 – Structure

Figure 1-3: LegoBody Tetraspecific Antibody Structure

Figure 1-4: LegoBody Tetra-N-Fab Post Thrombin Cleavage

Figure 2-1: Tetraspecific Antibody Structure

Figure 2-2: Tetraspecific Antibody Bringing T Cells & NK Cells In Close Proximity

Figure 3-1: Global – Tetraspecific Antibodies In Clinical Trials By Company, 2023

Figure 3-2: Global – Tetraspecific Antibodies In Clinical Trials By Country, 2023

Figure 3-3: Global – Tetraspecific Antibodies Clinical Trials By Indication, 2023

Figure 3-4: Global – Tetraspecific Antibodies In Clinical Trials By Phase, 2023

Figure 5-1: ANKET® Platform - Innate Pharma

Figure 5-2: GNC Antibodies - Sichuan Baili Pharmaceutical/SystImmune

Figure 5-3: STEALTH – ModeX Therapeutics

Figure 5-4: MSTAR – ModeX Therapeutics

Figure 5-5: Features of MSTAR

Figure 5-6: MATCH – Numab

Figure 5-7: Features of BiXAb

Figure 5-8: Zyngenia Technology Approach

Figure 5-1: Tetraspecific Antibody GNC035 Targeting Cell Surface Antigen CD3

Figure 5-2: Tetraspecific Antibody Engaging CD3 T cells

Figure 5-3: Tetraspecific Antibody GNC039 Targeting Co-Stimulatory Receptor 4-1BB

Figure 5-4: IPH6501 - Tetra-Specific NK Cell Engager

Figure 5-5: Tetraspecific Antibody GNC038 Targeting Immune Checkpoint Inhibitor PDL-1

Figure 5-6: Regulation of CD47 Signal From Cancer Cells By Tetraspecific Antibody

Figure 5-7: Novel Tetraspecific Format Developed By The Roche Pharma Research & Early Development

Figure 8-1: GNC-038 Phase I/II Study (NCT04606433) – Initiation & Completion Years

Figure 8-2: GNC-038 Phase I/II Study (NCT05192486) – Initiation & Completion Years

Figure 8-3: GNC-038 Phase I/II Study (NCT05485753) – Initiation & Completion Years

Figure 8-4: GNC-038 Phase I/II Study (NCT05623982) – Initiation & Completion Years

Figure 8-5: GNC-038 Phase I/II Study (NCT05627856) – Initiation & Completion Years

Figure 8-6: GNC-039 Phase I/II Study (NCT04794972) – Initiation & Completion Years

Figure 8-7: GNC-035 Phase I Study (NCT05039931) – Initiation & Completion Years

I would like to order

Product name: Tetraspecific Antibodies Clinical Trials, Proprietary Technologies, Companies & Market Trends Insight 2023

Product link: <https://marketpublishers.com/r/T9932404DF7AEN.html>

Price: US\$ 3,300.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T9932404DF7AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

